Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice

Intravitreal ranibizumab (IVR) has been approved for treating diabetic macular edema (DME), and is used in daily clinical practice. However, the treatment efficacies of IVR monotherapy in real-world clinical settings are not well known. The medical records of 56 eyes from 38 patients who received th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Shinri, Shinoda, Hajime, Nagai, Norihiro, Suzuki, Misa, Uchida, Atsuro, Kurihara, Toshihide, Kamoshita, Mamoru, Tomita, Yohei, Iyama, Chigusa, Minami, Sakiko, Yuki, Kenya, Tsubota, Kazuo, Ozawa, Yoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406051/
https://www.ncbi.nlm.nih.gov/pubmed/28422835
http://dx.doi.org/10.1097/MD.0000000000006459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406051/
https://www.ncbi.nlm.nih.gov/pubmed/28422835
http://dx.doi.org/10.1097/MD.0000000000006459

Ejemplares similares